A Phase 2 interventional study of PF-07275315 and Placebo in Asthma, sponsored by Pfizer. Recruiting at 137 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected.
This study is seeking participants who:
All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied.
PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 12 weeks. We will compare the experiences of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective.
Participants will be involved in this study for up to approximately 9.5 months depending on local requirements.
4,841 studies on the registry are indexed under Asthma; 600 are open to participants now.
This study's planned enrollment of 252 is above the median of 78 across 3,341 interventional studies indexed under Asthma.
Browse Asthma studies →Pfizer is the lead sponsor of 3,334 studies on the registry; 149 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 391 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 5, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must meet the following asthma criteria:
ACQ-5 score of ≥1.5 at screening visit and prior to randomization.
Other Inclusion Criteria:
Exclusion Criteria:
Medical Conditions:
Diagnosed with any of the following acute or chronic infections or infection history:
Prior/Concomitant Therapy:
Bronchial thermoplasty within the previous 24 months.
Prior/Concurrent Clinical Study Experience:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF-07275315
Drug: PF-07275315
PF-07275315
Drug: PF-07275315
PF-07275315
Drug: PF-07275315
Placebo
Other: Placebo
subcutaneous injection
subcutaneous injection
Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12
FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 is obtained from spirometry.
Time frame: Week 12
Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), and AEs/SAEs leading to treatment discontinuation
Incidence of treatment-emergent AEs, treatment-emergent SAEs, and treatment-emergent AEs/SAEs leading to treatment discontinuation
Time frame: Baseline through Week 24
Clinically significant, treatment-related laboratory abnormalities
Incidence of clinically significant changes in laboratory tests
Time frame: Baseline through Week 24
Clinically significant, treatment-related abnormalities in vital signs
Incidence of clinically significant changes in vital signs
Time frame: Baseline through Week 24
Clinically significant, treatment-related electrocardiogram (ECG) abnormalities
Incidence of clinically significant changes in ECG
Time frame: Baseline through Week 24
Change from baseline in pre-bronchodilator Percent (%) Predicted FEV1 at Week 12
Time frame: Week 12
Change from baseline in pre-bronchodilator FEV1 at all time points
Time frame: Baseline through Week 24
Change from baseline in pre-bronchodilator % Predicted FEV1 at all time points
Time frame: Baseline through Week 24
Change from baseline in pre-bronchodilator Forced Vital Capacity (FVC) at all time points
Time frame: Baseline through Week 24
Change from baseline in pre-bronchodilator % Predicted FVC at all time points
Time frame: Baseline through Week 24
Change from baseline in pre-bronchodilator FEV1/FVC Ratio at all time points
Time frame: Baseline through Week 24
Change from baseline in post-bronchodilator FEV1 at all time points
Time frame: Baseline through Week 24
Change from baseline in post-bronchodilator % Predicted FEV1 at all time points
Time frame: Baseline through Week 24
Change from baseline in post-bronchodilator FVC at all time points
Time frame: Baseline through Week 24
Change from baseline in post-bronchodilator % Predicted FVC at all time points
Time frame: Baseline through Week 24
Change from baseline in post-bronchodilator FEV1/FVC Ratio at all time points
Time frame: Baseline through Week 24
Percentage change from baseline in pre-bronchodilator FEV1 at all time points
Time frame: Baseline through Week 24
Change from baseline in pre-bronchodilator FEV1 at Week 12
Time frame: Week 12
Change from baseline in Asthma Control Questionnaire-5 (ACQ-5) total score at Week 12
Time frame: Week 12
Change from baseline in Asthma Quality of Life Questionnaire (AQLQ) global score at Week 12
Time frame: Week 12
Change from baseline in pre-bronchodilator FEV1 at Week 12 in participants with Fractional Concentration of Exhaled Nitric Oxide (FeNO) ≥25 ppb and <25 ppb
Time frame: Week 12
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 137 sites across 15 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tilrekimig